Leerink Partnrs Has Bearish Outlook for Geron Q4 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Leerink Partnrs decreased their Q4 2025 earnings estimates for shares of Geron in a research report issued to clients and investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.

A number of other equities analysts also recently commented on the stock. Barclays reaffirmed an "overweight" rating and issued a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC decreased their price target on shares of Geron from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday. Stifel Nicolaus dropped their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday. B. Riley downgraded Geron from a "buy" rating to a "neutral" rating and decreased their target price for the company from $3.50 to $2.00 in a research note on Thursday. Finally, HC Wainwright lowered Geron from a "buy" rating to a "neutral" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $5.68.

Remove Ads

Geron Stock Performance

Shares of GERN traded down $0.05 during mid-day trading on Thursday, hitting $1.71. The stock had a trading volume of 26,504,408 shares, compared to its average volume of 14,960,246. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.03 billion, a PE ratio of -5.34 and a beta of 0.53. Geron has a fifty-two week low of $1.46 and a fifty-two week high of $5.34. The company's fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $3.76.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts' consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million.

Institutional Investors Weigh In On Geron

Institutional investors have recently bought and sold shares of the stock. Alternative Investment Advisors LLC. raised its position in shares of Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company's stock worth $101,000 after buying an additional 2,612 shares in the last quarter. Rovin Capital UT ADV raised its holdings in Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 3,660 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Geron by 23.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 4,094 shares during the period. Xponance Inc. boosted its stake in Geron by 12.9% during the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 4,829 shares in the last quarter. Finally, US Bancorp DE boosted its stake in Geron by 68.4% during the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 7,429 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.